- Home
- CSCI vs PRPH Comparison
CSCI vs PRPH Comparison
Compare CSCI & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSCI
- PRPH
- Stock Information
- Founded
- CSCI 1990
- PRPH 1989
- Country
- CSCI Canada
- PRPH United States
- Employees
- CSCI N/A
- PRPH N/A
- Industry
- CSCI
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- CSCI
- PRPH Health Care
- Exchange
- CSCI NYSE
- PRPH Nasdaq
- Market Cap
- CSCI 9.9M
- PRPH 10.7M
- IPO Year
- CSCI 1996
- PRPH 1997
- Fundamental
- Price
- CSCI $3.34
- PRPH $0.37
- Analyst Decision
- CSCI
- PRPH
- Analyst Count
- CSCI 0
- PRPH 0
- Target Price
- CSCI N/A
- PRPH N/A
- AVG Volume (30 Days)
- CSCI 4.3K
- PRPH 748.2K
- Earning Date
- CSCI 05-13-2025
- PRPH 05-20-2025
- Dividend Yield
- CSCI N/A
- PRPH N/A
- EPS Growth
- CSCI N/A
- PRPH N/A
- EPS
- CSCI N/A
- PRPH N/A
- Revenue
- CSCI $9,030,000.00
- PRPH $6,770,000.00
- Revenue This Year
- CSCI N/A
- PRPH $221.82
- Revenue Next Year
- CSCI N/A
- PRPH N/A
- P/E Ratio
- CSCI N/A
- PRPH N/A
- Revenue Growth
- CSCI 127.46
- PRPH N/A
- 52 Week Low
- CSCI $1.96
- PRPH $0.22
- 52 Week High
- CSCI $11.10
- PRPH $5.62
- Technical
- Relative Strength Index (RSI)
- CSCI N/A
- PRPH 53.73
- Support Level
- CSCI N/A
- PRPH $0.30
- Resistance Level
- CSCI N/A
- PRPH $0.38
- Average True Range (ATR)
- CSCI 0.00
- PRPH 0.04
- MACD
- CSCI 0.00
- PRPH 0.01
- Stochastic Oscillator
- CSCI 0.00
- PRPH 75.27
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.